Lupin Gets USFDA Final Nod for Clobetasol Propionate Oint | CORPORATE ETHOS

Lupin Gets USFDA Final Nod for Clobetasol Propionate Oint

By: | May 7, 2018
lupin

May 7: Mumbai-based drug maker Lupin Ltd on Monday announced that it has received final approval for its Clobetasol Propionate Ointment USP, 0.05% from the United States Food and Drug Administration (USFDA).

“Lupin’s Clobetasol Propionate Ointment USP, 0.05% is the AB rated generic equivalent of Fougera Pharmaceuticals Inc.’s Temovate Ointment, 0.05%. It is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses,” the company said in a statement.

Clobetasol Propionate Ointment USP, 0.05% had annual sales of approximately $120 million in the US (IQVIA MAT January 2018).